Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Sotatercept clinical trials

Also listed in trial records as MK-7962, ACE-011, ActRIIA-IgG1Fc, Winrevair
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 9 trials in our UK, USA, France, Spain, Netherlands, Canada, Israel, Germany, Italy, Poland, Mexico, Australia, Japan, Belgium, Sweden, Czechia, South Korea, Taiwan, Denmark, Switzerland, Portugal, Brazil, China, Singapore, Turkey and India registers that name Sotatercept as an intervention. Synced 13 Nov 2026
9Current trials
6Recruiting now
4Lead sponsors
26Country registers
At a glance

Sotatercept is named as an intervention in 9 current clinical trials in our UK, USA, France, Spain, Netherlands, Canada, Israel, Germany, Italy, Poland, Mexico, Australia, Japan, Belgium, Sweden, Czechia, South Korea, Taiwan, Denmark, Switzerland, Portugal, Brazil, China, Singapore, Turkey and India registers. 6 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Merck Sharp & Dohme LLC (6). The most-studied condition is Pulmonary Arterial Hypertension.

Where Sotatercept is approved

All regulators →

Of the three regulators tracked here, the first to approve Sotatercept was the US, on 26 Mar 2024. It is approved in 3 of the 3 regulators tracked here.

USUnited States (FDA)
26 Mar 2024
Winrevair
BLA761363 on Drugs@FDA
First original NDA/BLA approval
EUEuropean Union (EMA)
22 Aug 2024
Winrevair
EMA product page
First centralised authorisation
CACanada (Health Canada)
28 Aug 2024
Winrevair
Notice of Compliance 33928
First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

Sotatercept patents and exclusivity

Expiry tracker →

Protections still running for marketed products containing Sotatercept, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.

EU European Commission, orphan market exclusivity
  • Winrevair for treatment of pulmonary arterial hypertension: until 27 Aug 2034. Union Register

Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.

What health systems spend on Sotatercept

All medicines →
ENNHS England
Not dispensed in the community in England in the last 12 months under this name
Net ingredient cost, community prescriptions
USUS Medicaid
$229.2m
12,448 prescriptions in 2025 · Winrevair
+377% on 2024
Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Sotatercept works

All drug targets →
  • Inhibin beta A chain inhibitor Inhibitor
    Target: INHBA inhibin subunit beta A
    ChEMBL only
Diseases it has been tested for in clinical trials, by furthest phase
  • Eisenmenger syndromePhase 2
  • AnemiaPhase 2
  • Anemia (phenotype)Phase 2
  • Beta thalassemiaPhase 2
  • Chronic kidney diseasePhase 2
  • Chronic myelomonocytic leukemiaPhase 2
  • Myelodysplastic syndromePhase 2
  • MyelofibrosisPhase 2
  • Non-small cell lung carcinomaPhase 2
  • Plasma cell myelomaPhase 2
11 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1743073, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12962, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Sotatercept

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Sotatercept. 1 is current, and 1 of it recommends it for at least some patients.

AppraisalNICE recommendationPublishedStatus
Sotatercept for treating pulmonary arterial hypertension
NICE TA1161
Optimised3 Jun 2026Current

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Sotatercept

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • IE
    Ireland: 2 products on the HPRA list
    Each product record links to the HPRA, which publishes the leaflet and SmPC.
  • EU
    European Union: Winrevair
    EMA product information: package leaflet and summary of product characteristics in every EU language.
  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Sotatercept

ChEMBL
CHEMBL1743073
DrugBank
DB12118
CAS number
1001080-50-7
FDA UNII
0QI90BTJ37
Wikidata
Q103815273
Wikipedia
Sotatercept

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

  • Recruiting667%
  • Active, closed333%

Trials by phase

  • Phase 2444%
  • Phase 4444%
  • Phase 3111%
01

Clinical trials of Sotatercept

9 trials
StudyPhaseStatusLead sponsorRegisters
Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)
NCT06658522 · ClinicalTrials.gov ↗ · Pulmonary Arterial Hypertension PAH, Pulmonary Arterial Hypertension WHO Group I, Pulmonary Arterial Hypertension
Phase 4 Recruiting Amsterdam UMC, location VUmc Netherlands
Sotatercept in Pulmonary Arterial Hypertension
NCT07140484 · ClinicalTrials.gov ↗ · Pulmonary Artery Hypertension
Phase 4 Recruiting University of Alberta Canada
A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy
NCT07356778 · ClinicalTrials.gov ↗ · Eisenmenger Syndrome, Pulmonary Arterial Hypertension of Congenital Heart Disease
Phase 4 Recruiting Kazuya Hosokawa Japan
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
NCT07600723 · ClinicalTrials.gov ↗ · Pulmonary Arterial Hypertension
Phase 4 Recruiting Merck Sharp & Dohme LLC India
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
NCT05587712 · Pulmonary Arterial Hypertension
Phase 2 Recruiting Merck Sharp & Dohme LLC UK, USA, Germany, France, Spain, Netherlands, Poland, Turkey, Australia, Israel
A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)
NCT07646860 · Pulmonary Arterial Hypertension
Phase 2 Recruiting Merck Sharp & Dohme LLC Japan
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
NCT07218029 · Pulmonary Arterial Hypertension
Phase 3 Active, closed Merck Sharp & Dohme LLC UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Czechia, Portugal, Canada, Brazil, Mexico, South Korea, Taiwan, Australia, Israel
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
NCT06814145 · Hypertension, Pulmonary
Phase 2 Active, closed Merck Sharp & Dohme LLC UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Canada, Mexico, Israel
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
NCT06925750 · Pulmonary Arterial Hypertension
Phase 2 Active, closed Merck Sharp & Dohme LLC UK, USA, China, France, Spain, Italy, Netherlands, Czechia, Canada, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Sotatercept across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

2 single-substance products containing Sotatercept on the HPRA medicines list.

All 2 Irish products →

Supply shortages

No entry for Sotatercept in the EMA, FDA or German BfArM shortage lists we track.

03

Conditions studied with Sotatercept

7 conditions
Pulmonary Arterial Hypertension6Hypertension, Pulmonary1Pulmonary Arterial Hypertension PAH1Pulmonary Arterial Hypertension WHO Group I1Pulmonary Artery Hypertension1Eisenmenger Syndrome1Pulmonary Arterial Hypertension of Congenital Heart Disease1
06

Related compounds

07

Questions about Sotatercept trials

How many clinical trials are testing Sotatercept?

9 current trials in our UK, USA, France, Spain, Netherlands, Canada, Israel, Germany, Italy, Poland, Mexico, Australia, Japan, Belgium, Sweden, Czechia, South Korea, Taiwan, Denmark, Switzerland, Portugal, Brazil, China, Singapore, Turkey and India registers name Sotatercept (also registered as MK-7962) as a drug or biological intervention, as of the registry sync on 13 November 2026. Completed and withdrawn studies are not counted.

Are Sotatercept trials recruiting patients?

Yes. 6 of the 9 trials are recruiting: 1 with sites in UK, 1 with sites in USA, 1 with sites in France, 1 with sites in Spain, 2 with sites in Netherlands, 1 with sites in Canada, 1 with sites in Israel, 1 with sites in Germany, 1 with sites in Poland, 1 with sites in Australia, 2 with sites in Japan, 1 with sites in Turkey and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Sotatercept clinical trials?

Merck Sharp & Dohme LLC (6), Amsterdam UMC, location VUmc (1), University of Alberta (1) and Kazuya Hosokawa (1). The number in brackets is how many trials each organisation leads.

Is Sotatercept licensed in Ireland?

Yes. The HPRA medicines list includes 2 single-substance products containing Sotatercept, for example Winrevair 45 mg powder and solvent for solution for injection (Merck Sharp & Dohme BV,). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Sotatercept shortage?

Not in the lists we track: Sotatercept has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Sotatercept works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sotatercept works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sotatercept (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 13 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.